Loading clinical trials...
Loading clinical trials...
Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma
Conditions
Interventions
Amivantamab
Locations
5
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Rogel Cancer Center - University of Michigan Health
Ann Arbor, Michigan, United States
Washington University - School of Medicine in St. Louis
St Louis, Missouri, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Start Date
August 5, 2022
Primary Completion Date
August 5, 2025
Completion Date
August 5, 2028
Last Updated
April 10, 2025
NCT05884320
NCT04704661
NCT05553782
NCT05483374
NCT04140526
NCT00939627
Lead Sponsor
Trisha Wise-Draper
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions